vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Ensysce Biosciences, Inc. (ENSC). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.9M, roughly 1.3× Ensysce Biosciences, Inc.). Ensysce Biosciences, Inc. runs the higher net margin — -147.0% vs -265.2%, a 118.2% gap on every dollar of revenue. Over the past eight quarters, Ensysce Biosciences, Inc.'s revenue compounded faster (107.9% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm specializing in developing innovative prodrug therapies for pain management and oncology indications. Its proprietary platform is designed to reduce opioid abuse risks while enhancing treatment efficacy, targeting global healthcare and pharmaceutical markets with a focus on unmet clinical needs.
BOLT vs ENSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.9M |
| Net Profit | $-6.6M | $-2.8M |
| Gross Margin | — | — |
| Operating Margin | -283.4% | -147.8% |
| Net Margin | -265.2% | -147.0% |
| Revenue YoY | — | 44.4% |
| Net Profit YoY | 58.4% | 22.3% |
| EPS (diluted) | $-9.38 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.9M | ||
| Q3 25 | $2.2M | $493.1K | ||
| Q2 25 | $1.8M | $1.4M | ||
| Q1 25 | $1.2M | $1.3M | ||
| Q4 24 | $0 | $1.3M | ||
| Q3 24 | $1.1M | $3.4M | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $-6.6M | $-2.8M | ||
| Q3 25 | $-7.1M | $-3.7M | ||
| Q2 25 | $-8.6M | $-1.7M | ||
| Q1 25 | $-11.0M | $-1.9M | ||
| Q4 24 | $-15.9M | $-3.6M | ||
| Q3 24 | $-15.2M | $661.8K | ||
| Q2 24 | $-21.2M | — | ||
| Q1 24 | $-10.8M | — |
| Q4 25 | -283.4% | -147.8% | ||
| Q3 25 | -355.1% | -758.7% | ||
| Q2 25 | -510.5% | -127.6% | ||
| Q1 25 | -991.4% | -149.1% | ||
| Q4 24 | — | -274.3% | ||
| Q3 24 | -1441.1% | 18.9% | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | — |
| Q4 25 | -265.2% | -147.0% | ||
| Q3 25 | -329.4% | -756.3% | ||
| Q2 25 | -474.6% | -126.4% | ||
| Q1 25 | -903.4% | -147.4% | ||
| Q4 24 | — | -273.4% | ||
| Q3 24 | -1330.1% | 19.4% | ||
| Q2 24 | -1662.4% | — | ||
| Q1 24 | -205.0% | — |
| Q4 25 | $-9.38 | $-0.51 | ||
| Q3 25 | $-3.72 | $-1.29 | ||
| Q2 25 | $-4.46 | $-0.79 | ||
| Q1 25 | $-0.29 | $-1.39 | ||
| Q4 24 | $-13.73 | $-0.89 | ||
| Q3 24 | $-7.93 | $1.00 | ||
| Q2 24 | $-11.12 | — | ||
| Q1 24 | $-0.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $4.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $3.2M |
| Total Assets | $56.7M | $7.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $4.3M | ||
| Q3 25 | $31.9M | $1.7M | ||
| Q2 25 | $34.8M | $2.2M | ||
| Q1 25 | $38.8M | $3.1M | ||
| Q4 24 | $47.3M | $3.5M | ||
| Q3 24 | $53.8M | $4.2M | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | $26.5M | $3.2M | ||
| Q3 25 | $32.1M | $1.2M | ||
| Q2 25 | $38.8M | $3.4M | ||
| Q1 25 | $46.8M | $3.0M | ||
| Q4 24 | $57.2M | $3.7M | ||
| Q3 24 | $72.0M | $6.9M | ||
| Q2 24 | $85.9M | — | ||
| Q1 24 | $104.2M | — |
| Q4 25 | $56.7M | $7.5M | ||
| Q3 25 | $65.1M | $3.2M | ||
| Q2 25 | $75.5M | $5.6M | ||
| Q1 25 | $85.9M | $4.6M | ||
| Q4 24 | $99.6M | $5.6M | ||
| Q3 24 | $109.3M | $9.4M | ||
| Q2 24 | $124.2M | — | ||
| Q1 24 | $142.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-1.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-1.5M | ||
| Q3 25 | $-9.7M | $-1.9M | ||
| Q2 25 | $-9.6M | $-2.7M | ||
| Q1 25 | $-13.4M | $-1.7M | ||
| Q4 24 | $-14.4M | $-764.1K | ||
| Q3 24 | $-14.0M | $-1.0M | ||
| Q2 24 | $-16.1M | — | ||
| Q1 24 | $-16.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
